Side-by-side comparison of AI visibility scores, market position, and capabilities
SF YC W20 psychiatric EHR for ketamine/psychedelic/TMS treatment practices; $55.2M total ($40M DFJ/General Catalyst/Tiger Series B May 2022) competing with Valant for emerging mental health treatment specialty EHR.
Osmind is a San Francisco-based psychiatry and mental health EHR (electronic health record) platform — backed by Y Combinator (W20) with $55.2 million in total funding including a $40 million Series B in May 2022 led by DFJ Growth with General Catalyst, Future Ventures, Tiger Global, Susa Ventures, Lachy Groom, and Pear VC — providing psychiatric practices with research-grade EHR technology specialized for emerging mental health treatments including ketamine therapy, psychedelic-assisted psychotherapy (psilocybin, MDMA), transcranial magnetic stimulation (TMS), and electroconvulsive therapy (ECT). Founded in 2020, Osmind captures clinical data during novel psychiatric interventions in structured formats that enable both optimized patient care workflows and real-world evidence research — serving the growing segment of psychiatric practices offering treatment-resistant depression interventions.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.